Long-Stay psychiatric patients: A prospective study revealing persistent Antipsychotic-Induced movement disorder

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bakker, P R ^a   de Groot, I W ^b   van Os, Jim ^c,d   van Harten, Peter N ^a,c  

^a Psychiatric Centre GGZ Centraal   (Netherlands)

^b Dimence   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; BRADYKINESIA; BRAIN TUMOR; CHRONIC DISEASE; CHRONIC PATIENT; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSTONIA; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; OROFACIAL DYSKINESIA; PARKINSONISM; PROSPECTIVE STUDY; PSYCHOSIS; RIGIDITY; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREMOR; AGE DISTRIBUTION; LENGTH OF STAY; MIDDLE AGED;

ADULT; AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS;

EID: 80053459019     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025588     Document Type: Article

References (69)

1. Casey DE, (2006) Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 11: 25-31.
2. Lambert M, Conus P, Eide P, Mass R, Karow A, et al. (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19: 415-422.
3. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, et al. (2002) Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 57: 209-219.
4. Ballesteros J, Gonzalez-Pinto A, Bulbena A, (2000) Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 20: 188-194.
5. Chong SA, Tay JA, Subramaniam M, Pek E, Machin D, (2009) Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol 29: 5-8.
6. Dean CE, Thuras PD, (2009) Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br J Psychiatry 194: 360-364.
7. Owens DGC, (1999) A guide to the extrapyramidal side-effects of antipsychotic drugs New York Cambridge University Press UK.
8. Factor SA, Lang AE, Weiner WJ, (2005) Drug induced movement disorders Malden, Mass Blackwell Futura.
9. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097.
10. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, et al. (2008) Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 193: 279-288.
11. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, et al. (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Jama 290: 2693-2702.
12. Lewis S, Lieberman J, (2008) CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 192: 161-163.
13. Leucht S, Corves C, Arbter D, Engel RR, Li C, et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
14. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, (2005) Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 66: 1130-1133.
15. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
16. Correll CU, Leucht S, Kane JM, (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414-25.
17. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, et al. (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079-1087.
18. Weiden PJ, (2007) EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 13: 13-24.
19. Janno S, Holi M, Tuisku K, Wahlbeck K, (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 161: 160-163.
20. van Harten PN, (1998) Movement disorders associated with neuroleptics: the Curacao extrapyramidal syndromes study Utrecht.
21. Correll CU, Schenk EM, (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21: 151-156.
22. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry.
23. Leucht S, Kissling W, Davis JM, (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 39: 1591-1602.
24. Taylor D, (2010) Antipsychotic polypharmacy- confusion reigns. The Psychiatrist 34: 41-43.
25. Fisher WH, Barreira PJ, Geller JL, White AW, Lincoln AK, et al. (2001) Long-stay patients in state psychiatric hospitals at the end of the 20th century. Psychiatr Serv 52: 1051-1056.
26. Procyshyn RM, Kennedy NB, Tse G, Thompson B, (2001) Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46: 334-339.
27. Broekema WJ, de Groot IW, van Harten PN, (2007) Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharm World Sci 29: 126-130.
28. Factor SA, Leffler JB, Murray CR, (2009) Drug-Induced Movement Disorders: A Clinical Review. Medscape, We Move:http://www.medscape.org/viewprogram/18880.
29. Esper CD, Factor SA, (2008) Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 23: 401-404.
30. Friedman JH, Fernandez HH, Trieschmann MM, (2004) Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol 17: 39-41.
31. Lerner V, Libov I, Kaptsan A, Miodownik C, Dwolatzky T, et al. (2007) The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci 44: 20-28.
32. van Harten PN, Matroos GE, Hoek HW, Kahn RS, (1996) The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 19: 195-203.
33. Sachdev PS, (2005) Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 28: 255-74, x.
34. American Psychiatric Association (APA) (1992) Tardive dyskinesia: a task force report of the American Psychiatric Association Washington The American Psychiatric Association.
35. Guy W, (1975) ECDEU assessment manual for psychopharmacology. Washington DC Department of Health, Education and Welfare pp. 534-537.
36. Guy W, (1976) ECDEU assessment manual for psychopharmacology Rockville, Md U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
37. Schooler NR, Kane JM, (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-7.
38. Fahn S, Elton R, (1987) UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease Florham Park, NJ Macmillan pp. 153-163.
39. Barnes TR, (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-6.
40. van Harten PN, Kahn RS, (1999) Tardive dystonia. Schizophr Bull 25: 741-8.
41. Burke RE, (1992) Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders New York Futura publishing company pp. 167-98.
42. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, et al. (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35: 73-7.
43. Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT, (2003) Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 23: 657-659.
44. Pappa S, Dazzan P, (2009) Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 39: 1065-1076.
45. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, et al. (2010) Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull 36: 723-731.
46. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, et al. (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 53: 313-9.
47. Modestin J, Wehrli MV, Stephan PL, Agarwalla P, (2008) Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 100: 97-107.
48. van Harten PN, Tenback DE, (2009) Movement disorders should be a criterion for schizophrenia in DSM-V. Psychol Med 39: 1754-1755.
49. Mittal VA, Walker EF, (2010) Letter to the Editor: Movement abnormalities and schizophrenia in DSM-V. Psychol Med pp. 1-3.
50. Tamminga CA, (2006) Practical treatment information for schizophrenia. Am J Psychiatry 163: 563-565.
51. Yassa R, Jeste DV, (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18: 701-15.
52. Tenback DE, van Harten PN, van Os J, (2009) Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 24: 2309-2315.
53. Keepers GA, Clappison VJ, Casey DE, (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40: 1113-7.
54. Richardson MA, Haugland G, Craig TJ, (1991) Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 148: 1322-8.
55. Barnes TR, Braude WM, (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42: 874-8.
56. Halstead SM, Barnes TR, Speller JC, (1994) Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 164: 177-83.
57. Hoffman WF, Bagdanoff MA, Keepers GA, (1994) Prevalence of tardive dystonia in a chronically mentally ill population. Neuropsychopharmacology 135S.
58. Sethi KD, Hess DC, Harp RJ, (1990) Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord 5: 319-21.
59. Soares-Weiser K, Fernandez HH, (2007) Tardive dyskinesia. Semin Neurol 27: 159-169 10.1055/s-2007-971169 [doi].
60. Leung JG, Breden EL, (2011) Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 45: 525-531 aph.1P312 [pii];10.1345/aph.1P312 [doi].
61. Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, et al. (2009) A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand 119: 269-273 ANE1115 [pii];10.1111/j.1600-0404.2008.01115.x [doi].
62. Slotema CW, van Harten PN, Bruggeman R, Hoek HW, (2008) Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry 32: 507-509 S0278-5846(07)00357-0 [pii];10.1016/j.pnpbp.2007.10.004 [doi].
63. van Harten PN, Hovestadt A, (2006) Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 21: 1276-1277 10.1002/mds.20904 [doi].
64. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, et al. (2003) Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 160: 1117-24.
65. Macpherson R, Collis R, (1992) Tardive dyskinesia. Patients' lack of awareness of movement disorder. Br J Psychiatry 160: 110-2.
66. Arango C, Adami H, Sherr JD, Thaker GK, Carpenter WT Jr, (1999) Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry 156: 1097-9.
67. Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Chiliza B, et al. (2010) Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry.
68. Laugharne J, Davies A, Arcelus J, Bouman WP, (2004) Informing patients about tardive dyskinesia: A survey of clinicians' attitudes in three countries. Int J Law Psychiatry 27: 101-108.
69. Fisher WH, Geller JL, Pandiani JA, (2009) The changing role of the state psychiatric hospital. Health Aff (Millwood) 28: 676-684.